Public Health
World Cervical Cancer Elimination Day 2026: Together We Can Eliminate Cervical Cancer
As the world marks World Cervical Cancer Elimination Day 2026, WHO is calling for stronger action to eliminate cervical cancer through HPV vaccination, regular screening and timely treatment. In Nigeria, expanding access to preventive services and improving public awareness remain essential to reducing the burden of this largely preventable disease
The world marks World Cervical Cancer Elimination Day on 17 November 2026, renewing attention to the global effort to eliminate cervical cancer as a public health problem. Under the theme "Together We Can Eliminate Cervical Cancer," this year's observance highlights the importance of HPV vaccination, regular cervical screening, early treatment and collective action to protect women and girls.
Established by World Health Organization (WHO) Member States in 2025, the annual observance provides a platform for governments, healthcare professionals, communities and advocacy organisations to strengthen commitments towards preventing cervical cancer and improving access to life-saving healthcare services.
According to WHO's November 2026 estimates, cervical cancer accounted for approximately 604,000 new cases and 280,000 deaths globally in 2024. The disease disproportionately affects women in low- and middle-income countries, where access to HPV vaccination, screening and appropriate treatment remains limited.
The continued burden highlights the urgent need to translate existing prevention strategies into accessible and sustainable healthcare services.
Cervical Cancer: A Preventable but Life-Threatening Disease:
Cervical cancer develops in the cervix, the lower part of the uterus that connects to the vagina. Almost all cases are associated with persistent infection with high-risk types of human papillomavirus (HPV), a common virus transmitted primarily through sexual contact.
Although most HPV infections clear naturally without causing health problems, persistent infection with certain high-risk HPV types can lead to abnormal changes in cervical cells, which may eventually develop into cancer if left untreated.
HPV types 16 and 18 are responsible for approximately 76% of cervical cancer cases globally, making prevention of these infections an important component of cervical cancer control.
Other factors, including weakened immune function, particularly among women living with HIV, and tobacco smoking, can increase the risk of developing cervical cancer.
One of the major challenges associated with the disease is that precancerous changes and early-stage cervical cancer may produce no noticeable symptoms. Consequently, some women are diagnosed only after the disease has progressed.
Cervical Cancer Burden in Nigeria:
Cervical cancer remains a major public health concern in Nigeria, where limited screening coverage, delayed diagnosis, inadequate access to treatment and low public awareness contribute to the disease burden.
According to the International Agency for Research on Cancer's (IARC) Global Cancer Observatory estimates for 2022, Nigeria recorded approximately 13,676 new cases of cervical cancer and 7,093 deaths.
These figures highlight the need to strengthen preventive healthcare services, improve early detection and expand access to appropriate cancer treatment across the country.
Nigeria made an important advancement in cervical cancer prevention in October 2023 when it introduced the HPV vaccine into its routine immunisation programme. The initial national rollout targeted girls aged 9–14 years, with a goal of reaching approximately 7.7 million girls.
The introduction of the vaccine represents a significant step towards protecting future generations against HPV-related cervical cancer.
However, sustained vaccination coverage, public education and expanded screening services remain essential to achieving Nigeria's cervical cancer elimination goals.
WHO's 90–70–90 Targets: A Roadmap to Elimination by 2030:
To accelerate global progress, WHO established the 90–70–90 targets as part of its Global Strategy to Accelerate the Elimination of Cervical Cancer as a Public Health Problem.
The strategy aims to eliminate cervical cancer as a public health problem by reducing its incidence to fewer than four new cases per 100,000 women annually.
The three targets to be achieved by 2030 are:
1. 90% HPV vaccination: Ensure that 90% of girls are fully vaccinated against HPV by the age of 15.
2. 70% cervical cancer screening: Ensure that 70% of women are screened using a high-performance test by the ages of 35 and 45.
3. 90% treatment: Ensure that 90% of women identified with cervical precancer or invasive cervical cancer receive appropriate treatment and care.
Achieving these targets requires coordinated efforts from governments, healthcare institutions, healthcare professionals, communities and international health organisations.
Importantly, elimination does not mean that every case of cervical cancer will disappear immediately. It means reducing the disease to a sufficiently low level that it no longer constitutes a major public health problem.
HPV Vaccination: The First Line of Prevention:
HPV vaccination remains one of the most effective strategies for preventing cervical cancer.
The vaccine protects against HPV types responsible for most cervical cancer cases and is particularly effective when administered before exposure to the virus.
WHO recommends HPV vaccination for girls aged 9–14 years, ideally before the onset of sexual activity. Vaccination schedules depend on age, immune status and applicable national recommendations.
Nigeria's introduction of HPV vaccination into its routine immunisation programme represents an important milestone in protecting future generations of women.
Parents and caregivers are encouraged to obtain accurate information from qualified healthcare professionals and ensure that eligible girls receive HPV vaccination through approved immunisation services.
However, HPV vaccination does not eliminate the need for cervical cancer screening. Vaccinated women may still be at risk from HPV types not covered by the vaccine or from infections acquired before vaccination.
Cervical Cancer Screening and Early Detection:
Regular cervical cancer screening is essential because precancerous cervical changes often develop without noticeable symptoms.
Screening helps identify high-risk HPV infections or abnormal cervical cells before they progress to invasive cancer, allowing appropriate follow-up and treatment.
WHO recommends high-performance cervical cancer screening beginning at age 30 for women in the general population and at age 25 for women living with HIV. The recommended screening intervals depend on the testing method and individual circumstances.
Available screening methods include:
- HPV DNA testing: Detects high-risk HPV types associated with cervical cancer and is WHO's preferred primary screening method.
- Visual inspection with acetic acid (VIA): Uses a dilute acetic acid solution to identify abnormal areas of the cervix.
- Cervical cytology (Pap smear): Examines cervical cells for abnormalities that may indicate precancerous changes or cancer.
Women with abnormal screening results should receive appropriate follow-up investigations and treatment according to established clinical guidelines.
Improving access to affordable screening services, particularly in rural and underserved communities, is essential to reducing preventable deaths.
Recognising Possible Warning Signs:
Although early cervical cancer and precancerous changes may not produce symptoms, women should be aware of possible warning signs, particularly as the disease progresses.
These include:
• Vaginal bleeding after sexual intercourse.
Bleeding between menstrual periods or after menopause.
• Unusual or foul-smelling vaginal discharge.
Persistent pelvic, lower back or leg pain.
Discomfort during sexual intercourse.
•.Unexplained weight loss, fatigue or swelling of the legs, particularly in advanced disease.
These symptoms do not necessarily indicate cervical cancer, as other medical conditions can cause similar problems. However, women experiencing unusual or persistent symptoms should seek prompt medical assessment rather than wait for their next routine screening appointment.
The Role of Pharmacists and Other Healthcare Professionals:
Pharmacists and other healthcare professionals have important roles in supporting cervical cancer elimination through patient education, preventive healthcare advocacy, early identification of possible warning signs and appropriate referral.
Pharmacists can contribute by:
- Educating individuals and families about HPV infection, transmission and prevention.
Promoting awareness and acceptance of HPV vaccination.
- Encouraging eligible women to access regular cervical cancer screening.
- Addressing misconceptions and misinformation surrounding HPV vaccines.
- Identifying possible warning signs and referring individuals for appropriate medical evaluation.
- Supporting patients receiving cancer treatment through medication counselling, adherence support and information about supportive care.
- Participating in community health campaigns and public health education programmes.
- Pharmacists can also collaborate with physicians, nurses, laboratory scientists, public health professionals and policymakers to improve awareness and strengthen access to comprehensive cervical cancer prevention and care.
Such collaboration is particularly important in communities where misconceptions, financial barriers and limited healthcare facilities prevent women from accessing preventive services.
Moving Towards a Cervical Cancer-Free Future:
As the world marks World Cervical Cancer Elimination Day 2026, the message remains clear: cervical cancer elimination is achievable, but it requires sustained commitment, adequate investment and collective responsibility.
Governments must strengthen healthcare systems, expand HPV vaccination programmes, improve access to high-quality screening and ensure that women diagnosed with cervical precancer or cancer receive timely and appropriate treatment.
Healthcare professionals must continue to promote preventive healthcare, provide accurate information and support early detection, while communities must challenge misconceptions and encourage women and girls to access available services.
For Nigeria, accelerating cervical cancer elimination will require stronger investment in women's health, sustainable vaccination coverage, accessible screening programmes and improved cancer diagnosis and treatment services.
No woman should lose her life to a disease that can largely be prevented, detected early and successfully treated. Through HPV vaccination, regular screening, timely treatment and sustained public health action, a cervical cancer-free future is within reach.
References:
1. World Health Organization (WHO). (2026). World Cervical Cancer Elimination Day 2026: Together We Can Eliminate Cervical Cancer.
2. World Health Organization (WHO). (2026). Cervical cancer: Fact sheet. 10 November 2026.
3. World Health Organization (WHO). (2026). Countries expand cervical cancer screening and treatment, bringing elimination closer. 17 November 2026.
4. International Agency for Research on Cancer (IARC). (2024). Global Cancer Observatory: Nigeria Fact Sheet, GLOBOCAN 2022.
5. World Health Organization Regional Office for Africa. (2023). Nigeria to vaccinate 7.7 million girls against leading cause of cervical cancer. 24 October 2023.
6. World Health Organization (WHO). (2020). Global strategy to accelerate the elimination of cervical cancer as a public health problem.